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It is probable that certain characteristics of the patient, as well as 
the inherent qualities of the organism, determine differences in  the 
degree of immunity to attack, in the clinical course, in the pathological 
lesions, and in the outcome of pneumococcic  pneumonia.  Little direct 
information has been obtained of variations in individuals or popula- 
tion groups which might influence the incidence or nature of the disease. 
Clinical  observation (1-3)  has  indicated,  however,  that  there  are 
groups,  notably those of  different ages, in which the disease picture 
and outcome of pneumonia has characteristics which differ from those 
in other groups.  It appears, also from clinical data, that pneumonia 
due to the Type I  pneumococcus is consistently more frequent than 
pneumonia due to other types, suggesting the  possible  existence  of 
differences in susceptibility to attack by the individual types of pneu- 
mococci.  The  study presented  below was  undertaken in  order  to 
secure information that might be compared with these clinical observa- 
tions.  Groups of normal persons of different ages were examined by 
means of several of the methods of immunity.  The possibility was 
entertained  that  certain  differences in  immune reactions  with  age 
would suggest the existence of relationships between these immune 
reactions and the age variations in incidence, character, or outcome 
of pneumococcic  pneumonia. 
Methods  were  selected which involved the  use  of pneumococcus 
type-specific antigens and pneumococcus  species-specific antigens.  Of 
the former were the whole blood pneumococcidal test, the mouse pro- 
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tection test, the agglutinin test,  and the skin reaction to the pneumo- 
coccus polysaccharide.  Of the latter were the skin  test  to the pneu- 
mococcus protein  and  the  skin  test  to the pneumococcus autolysate. 
These methods have occasionally been used separately in studies of sus- 
ceptibility to infection with the pneumococcus or related organisms. 
A method similar  to the whole blood pneumococcidal  test  has been  used  by 
Robertson and Sia  (4)  in studying the resistance  to pneumococcus  infection  in 
common laboratory animals.  In the rabbit,  guinea pig, dog, and cat, the growth- 
inhibitory action of serum, when mixed with a standard suspension of leucocytes, 
varies  as the natural resistance  of the animal  to infection by the pneumococcus. 
Determinations  of the ability of the blood of normal adult human beings to kill 
pneumococci have been made by Sutliff and Rhoades  (5) for Type I pneumococci 
and by Ward (6)  for pneumococci of Types I, II, and III.  Marked variability 
was found among individuals with respect to the number and type of pneumococci 
killed. 
Mouse-protective  antibodies  for the pneumococcus  were  noted in  the  blood 
serum of normal  individuals  by Neufeld  (7), and have been studied  by Clough 
(8), by Cecil and Austin (9), and by Gundel and Sch~fer (10).  They are not so 
frequently present  as whole blood bactericidal  power and are usually of low titer. 
Type-specific agglutinins  are thought not to be present  in normal human sera 
(8).  A test for the presence of species agglutinius for an avirulent  strain of pneu- 
mococcus was recently employed by Blake  (12).  The sera from normal subjects 
and those with a variety of diseases of various ages were examined using the liv- 
ing culture of a  degraded  avirulent  pneumococcus as the antigen.  By charting 
theincidence of subjects of different ages who had an agglutinin  titer greater than 
1:320, a curve was obtained which is similar to that shown below for whole blood 
pneumococcidal  power. 
A considerable incidence of positive  skin reactions  to the specific soluble sub- 
stance of the pneumococcus among normal adults has been reported by Finland 
and Sutliff  (11). 
Clinical Material and Methods 
The subjects were patients in the wards and outpatient department of the hospi- 
tal and were chosen because they gave no history of having had pneumonia  or a 
recent  acute upper respiratory infection.  For the most part those from 2 to 83 
years of age were in the hospital for the following conditions:  fractures,  non-septic 
wounds, convalescence from surgical operations,  functional  disorders, and chronic 
degenerative  disease, notably essential  hypertension,  chronic  hypertrophic ar- 
thritis,  and generalized  arteriosclerosis.  About one-half  of the children  from 2 
to 6 years of age were studied  late in convalescence from diphtheria  or scarlet 
fever.  The infants less than 10 days of age were normal, and the infants from 3 
weeks to 2 years of age were brought to the out-patient department for regulation 
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The pneumococcidal power of the whole defihrinated blood was determined for 
pneumococci of Types I, II, and III by a  method similar  to that of Ward  (6). 
Measured quantities of culture were secured, uncontaminated by the blood ceils 
used for enrichment of the medium, by removing 0.5 cc. of the upper portion of the 
culture and diluting, successively, 0.5 cc. with 4.5 co. quantities of meat infusion 
broth.  0.1  cc. of each dilution containing amounts of culture ranging from 10  -2 
to 10  -8 cc. were added to 0.5 cc. amounts of defibrinated blood in Pyrex tubes, 
sealed by means of a  gas-oxygen flame and incubated while rotating slowly end 
for end during 18 to 24 hours.  At the end of this time the color change in the 
tubes was noted, and 1 loopful was planted on blood agar plates to confirm the 
presence or absence of growth of organisms.  The dilution method of measuring 
the number of organisms was controlled by culturing 1 cc. of the dilution contain- 
ing 10  -7 cc. of the original culture.  A variation of from 30 to 170 organisms was 
found.  The results in the blood tubes that received less than 30 to 170 organisms 
were discarded, and only persons 0.5 cc. of whose blood killed from 30 to 170 or 
more organisms were listed as having pneumococcidal power. 
The mouse protection tests were done by the usual technique. 
Agglutination tests of the sera against Type I, Type II, and Type III pneumo- 
cocci were performed, as described by Tillett and Francis (13). 
Three materials derived from the pneumococcus were used for skin tests, namely, 
soluble specific substances, acetic acid-precipitable proteins, and autolysates. 
The soluble specific substances for Types I, II, and III were made by the method 
of Heidelberger and Avery, (14, 15) and supplied through the courtesy of Dr. W. 
S. Tillett of the Hospital of The Rockefeller Institute.  They were injected intra- 
dermally in 0.1  cc.  amounts of a  dilution in normal saline containing 0.01  rag., 
together with a  normal saline control.  The wheal and erythematous skin reac- 
tions elicited by these materials have been described by Tillett and Francis (13). 
A wheal 0.8 cm. in diameter with erythema 1.5 cm. in diameter was considered 
positive. 
The acetic acid-precipitable proteins of the pneumococcus were made according 
to Woolridge's method, as used by Avery and Morgan (16)  and as adapted for 
the  hemolytic  streptococcus  by  Lancefield  (17).  Filtering  the  streptococcic 
protein solution through a Berkefeld V candle before sealing in vials was the only 
departure  from the  chemical procedures outlined  by the above authors.  Five 
different protein substances were prepared at one time from four strains of pneu- 
mococci and one strain of hemolytic streptococcus and used in the course of 5 
months.  One virulent  Type I  pneumococcus, one avirulent  pneumococcus de- 
rived  from a  Type I  pneumococcus, one virulent  Type II pneumococcus, one 
avirulent pneumococcus derived from a  Type II strain,  and one Dick strain of 
Streptococcus scarla~inae were used.  The preparations were standardized on the 
basis  of  their  protein  content,  as  measured  by  total  nitrogen determinations. 
Concentrated solutions in physiological saline were made neutral to phenolphthal- 
ein by means of the addition of a small amount of NaOH, and were kept in rubber- 
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0.1 cc., contained 0.01 mg. or 0.1 mg.  The protein of the scarlatinal streptococcus 
was used in a dilution such that 0.1  cc. contained 0.02 mg.  The skin  reactions 
elicited by the pneumococcic proteins injected intradermally were characteristic 
at the end of 24 hours and appeared very much like the skin response to tuberculin. 
The reaction has been described by Tillett and Francis (13).  An erythema 1.0 
cm. in diameter was considered  positive.  The protein of the scarlatinal strepto- 
coccus elicited  more marked and more frequent reactions, but of quite a similar 
character. 
Autolysates were prepared from three different strains of pneumococci,  namely, 
from a virulent Type I, from an avirulent organism derived from a Type I pneu- 
mococcus, and from a virulent Type II.  The method of Zinsser and Grinnell (18) 
was followed with the addition of subsequent heating, as done by Sharp and Blake 
(19).  These preparations were also standardized by means of the protein content, 
and were used in dilutions such that 0.1  cc. contained 0.1 or 0.01 mg.  The skin 
reactions to the autolysates were similar to those to the pneumococcus proteins 
both in form and occurrence;  except that, in addition to the rather frequent oc- 
currence of a diffuse non-specific erythema within the 1st hour after the adminis- 
tration of the test, occasional  definite wheal and erythema reactions, which faded 
within the first 30 to 60 minutes, occurred with one or another autolysate. 
As many as 20 skin tests were done simultaneously in a number of cases,  in 
which both 0.1 and 0.01 rag. of each protein and each autolysate were used.  The 
usual  number of skin  tests done  simultaneously was  8 to  16.  Readings  were 
made 20 to 30 minutes after the injections and again at the end of 18 to 24 hours. 
FINDINGS 
Pneumococcidal  Action of Whole Blood 
The number of organisms killed by 0.5 cc. of defibrinated  blood va- 
ried  in  different  individuals  from approximately 10 to approximately 
1,000,000.  There  was  little  difference  between  the  three  pneu- 
mococcus types or between the subjects of different age groups in the 
number of organisms disposed of.  Of the  subjects  whose  tests were 
positive against pneumococd of Type I, Type II,  or Type III, 83 per 
cent, 78 per cent, and 90 per cent killed, respectively, 10,000 organisms 
or less;  17  per  cent,  18  per cent,  and  8  per  cent killed,  respectively, 
100,000 organisms; and none, 3.2 per cent, and 1.6 per cent killed,  re- 
spectively,  1,000,000  organisms.  The  data  presented  below  contain 
only  the  inddence  of pneumococddal  power without  relation  to  the 
number of organisms killed. 
The incidence of whole blood pneumococcidal power was determined 
for Type I, Type II, and Type III pneumococci in 112 individuals of va- W.  D.  SUTLIFF  AND  ~_AXV~ELL  FINLAND  841 
rying ages, and for the mothers of the 22 infants less than 10 days of age. 
The distribution of these individuals in eight different groups and the 
percentage of each group, whose blood was pneumococeidal for Type 
I, Type II, and Type III, are shown in Fig.  1.  The mothers, whose 
ages ranged from 19 to 33, showed an incidence of bacteriddal power 
similar to that of normal adults.  Among the new-born infants and 
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FIG. 1 
those in the first  10  days of life,  bactericidal power was frequently 
present.  In later infancy, from the age of 3 to 5 weeks and from 2 to 
15  months, it was absent or quite rare.  In childhood from 2 to  11 
years pneumococcidal  power was again as frequent as among new-born 
infants.  The highest incidence for all  three types of pneumococci 
was reached among adults.  There was  moderate drop in old age. 842  ANTIPNEUMOCOCCIC  IMMUNITY  REACTIONS 
The number of subjects who had no pneumococcidal power for any 
of the three types varied as would be expected with the general inci- 
dence of pneumococcidal action.  4 of 22 infants less than 10 days of 
age had no pneumococcidal  power, 15 of the 18 infants from 3 weeks to 
15 months of age had none, and i child among the 22 from 2 to 11 years 
had none.  Among 20 adults 19 to 39 years of age, all the subjects 
killed pneumococci of at least one type.  4 of the 30 persons over 56 
years of age had no pneumococcidal  power. 
A striking characteristic of the bactericidal power of the 22 infants, 
ranging from birth to  10 days of age,  and their mothers, examined 
simultaneously, was that in every case the bactericidal power of the 
infant, although slightly less in degree, was a qualitative reproduction 
of its own mother's bactericidal power.  The infants sometimes lacked 
bactericidal power for one or more pneumococcus types, as is indicated 
by the lower incidences in Fig.  1,  but this occurred only when the 
blood of the mother killed few pneumococci. 
The relative frequency of bactericidal power against the three types 
of pneumococci can be studied in Fig. 1.  The relationship is the same 
in each age group.  Bactericidal power is least frequent for Type I, 
is most frequent for Type II, and is intermediate in frequency for 
Type III. 
In the individual blood samples each of the eight possible combina- 
tions of type-specific pneumococcidal power appeared.  Some com- 
binations, such as Type I  negative with  Types II and III positive, 
occurred frequently, while others, such as Types I  and III positive 
with Type II negative, were rare. 
The frequency, with which each of these combinations could be ex- 
pected, was calculated, by means of the mathematical law of probabil- 
ity, from the frequency with which killing was found for each type indi- 
vidually.  The result for each of the possible combinations was almost 
identical with the frequencies actually observed, indicating that these 
combinations arose according to the laws of chance.  It would appear 
likely that the pneumococcidal  power for any one type originates inde- 
pendently of the pneumococcidal action against other types. 
In  summary, bactericidal power of the  blood  for pneumococci of 
Types I, II, and III may be described for five age groups with differing 
incidences.  (1)  It is nearly as frequent in the first 10 days after birth W.  D.  SUTLIFF  AND  MAXWELL  :FINLAND  843 
as in adults.  Each individual infant resembles its own mother in the 
pneumococcidal power it possesses.  (2)  Infants from 3 weeks to  15 
months of age have little or no blood pneumococcidal  power.  (3)  The 
incidence among children from 2 to 11 years of age is somewhat less 
than among adults.  (4)  The highest incidence is found between the 
ages 19  to 39 in adult life.  (5)  The incidence among persons from 
56 to 83 years of age is somewhat less than among younger adults. 
The relative incidence for the three common  immunologically  specific 
varieties of the organism is similar in all the age groups studied; Type I 
is least often killed,  Type II is most frequently killed, and Type III 
occupies an intermediate position.  The associations of killing power 
specific for type in individuals appear to be subject to  the laws of 
chance. 
Mouse Protection 
Serum antibodies were determined by the  mouse protection test 
for 9 infants at birth, 15 infants 3 weeks to 15 months of age, 5 children 
from 2 to 11 years, 20 adults from 19 to 39 years, and 30 persons from 
56 to 83 years of age.  The incidence of positive tests was low, varying 
from 0 to 3 per cent for Type I, from 0 to 22 per cent for Type II, 
and from 0 to 22 per cent for Type III.  None of the 15 infants aged 
3 weeks to 15 months had mouse-protective antibodies in their serum 
against pneumococci of Type I, II, or III.  No other definite trend 
with age could be made out.  When the tests for all age groups are 
added together, the relative incidence of mouse protection for the three 
pneumococcus types is the same as the total relative incidence of pneu- 
mococcidal power for the three types.  Type I protection is the least 
frequent, Type II is the most frequent, and Type III protection occu- 
pies the middle position. 
Agglutination 
The number of positive type-specific agglutinations was quite small. 
Among 142 patients tested, 2 showed agglutination for Type I pneumo- 
cocci, 3 showed agglutination for Type II pneumococci, and 12 showed 
agglutination for Type III pneumococci.  The titers ranged from 1:4 
to 1:16.  Here, again, none of the infants from 3 weeks to 15 months 
of age showed specific agglutinins. 844  ANTIPNEUMOCOCCIC  IMMUNITY  REACTIONS 
Skin Reactions to the Soluble Specific Substances 
Skin tests with the soluble specific substances of the  three pneumo- 
coccus types were done in all five groups of patients and  the  results 
are shown in Table I.  In infants less than  15 months of age, an ery- 
thema was invariably produced which obscured any immediate specific 
erythematous reaction.  No wheal formation was observed.  There is 
no significant difference in the incidence of positive reactions in chil- 
dren, adults, and old persons.  The relative incidence of positive skin 
reaction to the three type-specific carbohydrates is of interest.  Type 
I  carbohydrate caused skin reactions least frequently, Type n  carbo- 
hydrate caused skin reactions most frequently, and reactions to Type 
In  carbohydrate occurred with intermediate frequency. 
TABLE  ] 
The  Age  Distribution  of Positive  Skin  Reactions  to Pneumococcic  Type-Specific 
Carbohydrates among tIospital Patients with No History of Pneumonia 
No. of subjects with positive reactions 
Skin test substance 
Birth to 
10 days 
Type  I  S.S.S. 0.01 mg ...................  ? 
"  II  "  0.01 " ...................  ? 
"  In  "  0.0i " ...................  ? 
No. of subjects tested ..................  11 
$ wks. to  2 to  19 to 
15 mos.  11 yrs.  39 yrs. 
1  1 
?  5  3 
?  2  0 







? =  erythema occurred regularly.  No wheals were observed. 
Skin Reactions to Acetic Acid-Precipitable Protein and to Autolysate 
Among the acetic acid-predpitable proteins  derived  from 4  strains 
of pneumococci and used in two different concentrations,  all showed 
an  increasing  percentage  of positive  reactions  with  age.  Variations 
in the incidence of positive reactions were observed with the protein 
from different strains  and still more marked  variations  in  incidence 
were seen when the amount of protein was varied from 0.1 to 0.01 ms. 
Individual subjects who did not react to all  these pneumococcic pro- 
teins,  gave positive reactions to different preparations.  The  results 
with the autolysates of three strains of pneumococci were similar,  ex- 
cept that  a  slightly  higher  proportion  of the  subjects gave positive W.  D.  SUTLIFF  AND  MAXWELL  FINLAND  845 
reactions.  The positive reactions to the streptococcic protein were in 
turn,  more numerous  than  those  to  the  pneumococcic autolysates. 
Marked differences in the incidence of positive reactions resulting from 
small changes in the concentration of the same protein or autolysate 
indicate that the concentration  must  be  carefully controlled.  It is 
further possible that chemical determinations of the nitrogen content 
of such complex solutions may not indicate the concentration of other 
substances, which can alter the incidence of positive reactions.  On ac- 
count of such factors and also on account of the small number of obser- 
•  cations, the actual incidences reported here are not of great significance. 
The general trend with age, however, is quite clear and is similar for 
TABLE  I.~ 
The  Age  Distribution  of Positive  Skin  Reactions  to  Pneumococcic  Protein  and 
Autolysate  among Hospital  Patients with No History  of Pneumonia 
Skin test substance 
Pneumococcic protein 0.1 rag. Type I  (aviru- 
lent) .................................. 
Pneumococcic  autolysate  0.1  nag.  Type  II 
(virulent)  .............................. 
Streptococcic protein 0.1 rag. Dick Streptococ- 
cus scarlatinae .......................... 
No. of subjects tested ................... 





























all three types of substances.  An increase occurs from no reactions, or 
few reactions, at birth to a rather high incidence of reactions in the age 
group 2 to 11 years as is shown in Table II. 
Correlations between the Tests 
Type-specific antibodies, indicated by the mouse protection test and 
the agglutination test, were always confirmed by the presence of type- 
specific whole blood pneumococcidal power in the same blood sample. 
The whole blood pneumococcidal test was positive frequently in the 
absence of demonstrable serum antibodies, as would be expected from 
its greater sensitivity, noted by Sutliff and Rhoades (5), and from the 846  ANTIPNEUMOCOCCIC  IMMLrNITY  REACTIONS 
greater sensitivity of the growth-inhibitory action of serum-leucocyte 
mixtures, noted by Robertson and Sia (4).  The skin reactions to the 
soluble specific substance were not correlated with other specific anti- 
bodies.  This  is  surprising  in  view of  the  strict  association  with 
type-specific  antibodies in the course of lobar pneumonia (11, 13).  Skin 
reactions to the pneumococcic protein and streptococcic protein and 
pneumococcic autolysate were not correlated with any other tests. 
DISCUSSION 
Four of the methods  described  above,  namely whole blood bac- 
tericidal tests, mouse-protective tests, skin tests performed with pro- 
tein solutions,  and skin tests performed with autolysates, showed an 
incidence of positive reactions that varied with age.  Skin tests with 
autolysates and  proteins were  quite  similar  in  their incidence and 
will be discussed together.  Agglutinin reactions were so seldom posi- 
tive that comparisons of their incidence in different age groups are not 
significant.  Type-specific skin tests were not successfully interpreted 
in infants and showed no variations in incidence in other age groups. 
The results of the tests that varied in their incidence of positive reac- 
tions with age may be compared with the scattered results previously 
obtained by others. 
The incidence of adult subjects possessing  pneumococcidal power 
was much less than that found previously by Sutliff and Rhoades (5), 
who used a  somewhat different method, and by Ward (6).  These 
authors found the normal incidence among adults of killing power for 
the Type I pneumococcus  to be 66 and 70 per cent, respectively,  as com- 
pared with 26 per cent found here.  Ward reported an incidence of 100 
per cent for pneumococcidal  power for Types II and III in 10 subjects, 
in contrast to 90 per cent and 70 per cent, respectively, reported above. 
It is possible that the organisms used in the present work had greater 
virulence, when measured against human blood,  than  those of the 
investigators quoted, since they were passed daily through mice, were 
transferred at 8 hour intervals in media enriched by rabbit blood, and 
were diluted for use together with the surrounding culture fluid. 
Mouse protection tests of the sera showed that the general incidence 
of these type-specific  antibodies is low and that infants from 3 weeks to 
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other age groups.  Gundel and Schafer (10) reported similarly that 
infants do not have mouse-protective antibodies.  The incidence of 
protection for Type I among adults is lower than that found by Sutliff 
and Rhoades (5) but, since the same cultures were used for pneumococ- 
cidal tests and for protection tests in mice in both studies, the possibil- 
ity is again suggested that the virulence of the cultures differed. 
The frequency of skin reactions to the acetic acid-precipitable pro- 
teins and the autolysates of the pneumococcus, increases with age in a 
manner similar to that found by Derrick and Fulton (20) for similar 
tests with proteins derived from Streptococcus hemolyticus  and Strepto- 
coccus viridans. 
The nature of the antibodies in normal persons which have given rise 
to the positive reactions may be described in immunological terms. 
Positive whole blood bactericidal tests and mouse protection tests de- 
pend upon the presence of type-specific opsonins in the serum of the 
individual.  The cells of the whole blood and of the mouse, while essen- 
tial to the reactions, play a passive part (4).  The apparent independ- 
ence of the reaction against  any one pneumococcus type from that 
against any other  suggests that the opsonins in normal persons are 
type-specific in character, as they are in persons who have recovered 
from the disease.  In case of the skin reactions to the pneumococcic 
protein, however, the antigen is  species-specific  in the type of anti- 
bodies that its injection produces and in its reactions with antipneu- 
mococcic  sera.  In contradistinction to type-specific  antibodies, TiUett 
and Francis (13) have noted no association of positive skin reactions 
to protein in patients recovering from lobar pneumonia with the ap- 
pearance of serum antibodies against the pneumococcic protein.  By 
their occurrence in the same patients and the similar nature of the re- 
action, the positive tests to injection of the autolysates seem probably 
due to the same sort of mechanism as the positive tests to the pneu- 
mococcic protein. 
The incidence of these positive  reactions may be  discussed with 
relation to possible modes of development and with relation to a possi- 
ble correlation with clincal observations. 
The mode of origin of the reactions to type-specific and species-spe- 
cific antigens is suggested by some of the characteristics of their occur- 
rence.  The type-specific antibodies at birth were similar to those of 848  ANTIPNE~OCOCCIC  IMMUNITY  REACTIONS 
the mother and disappeared before the age period 3 to 5 weeks.  This 
suggests a  passive transfer of such antibodies through the placenta 
from mother to child. 
After 2 years of age, the type-specific antibodies appear with con- 
siderable frequency and in combination according to the laws of chance. 
This seems to point toward a chance contact with specific organisms as 
the cause of their development.  A carrier state, usually of short dura- 
tion for Type I  and Type II pneumococci, but longer for Type III 
pneumococci, was  demonstrated in  one-half  of  a  group  of  normal 
subjects during the course of 7 months by Powell, Atwater, and Felton 
(21) and has been confirmed by Webster (22).  Whether such contact 
leads to the production of antibodies has not been determined, but the 
slight specific stimulus needed for antibody production noted in the 
following study (23) suggests that the presence of a few organisms on a 
mucous  membrane  might  be  effective.  In  following  further  the 
suggestion that contact with organisms leads to the production of the 
type-specific antibodies, a number of factors that could influence their 
production must be considered.  In the first place, the relative effi- 
ciency of the pneumococci in inducing type-specific antibody produc- 
tion may vary.  It has been shown (24) that the Type III pneumococ- 
cus is relatively much less efficient in rabbits than Type I or Type II. 
The relative frequency of opportunities for contact of an individual 
with  the  three  pneumococcus types presented by  the  work of  the 
authors above is, in the order from least to greatest frequency, I, II, 
III; but  the  relative frequency with  which type-specific antibodies 
were demonstrated here is,  in the same order, I, III, II.  Type III 
thus has  an  anomalous position.  Although contact with Type  III 
pneumococcus is most often observed,  antibodies for Type III  are 
less often seen than antibodies for Type II.  The Type III pneumo- 
coccus may thus be less efficient than Type I and II in the production 
of specific antibodies in man.  Other factors may further modify the 
production of antibodies by contact.  In the individual subject the 
site of the organisms, whether in a normal pharynx or a purulent focus, 
may influence their effectiveness as antigens.  The responsiveness of 
the antibody-producing cells of individuals may vary.  It is also possi- 
ble that antigens derived from organisms other than the pneumococcus 
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Although it seems likely that contact with pneumococci that does 
not lead to the production of pneumonia may lead to the production of 
type-specific antibodies and thus be the determining factor in their 
development during childhood, the question requires further clarifica- 
tion.  There are alternative possible methods for the development of 
antibodies in normal persons.  It has been suggested (27) that normal 
processes in the growth and maturing of the body or certain organs 
may underly the development of natural antibodies.  A combination 
of physiological changes and contact with antigens is also possible. 
The negative skin tests to protein and autolysate in the new-born 
infants indicate that reactions to species-specific antigens are not pas- 
sively transferred from the mother.  This is opposed to the observa- 
tions of Julianelle  (28)  who found that  experimentally  induced in- 
creased  skin  reactivity  to  the  protein  of  the  pneumococcus was 
associated with the presence of circulating species-specific antibodies 
and was transferable by means of the intravenous administration of 
serum to another animal.  He also found, however, that the increased 
sensitivity to heat-killed vaccines was not associated with the presence 
of antibodies and was  not transferable.  Furthermore, experimental 
studies of allergic skin reactions to pneumococcus autolysates in ani- 
mals by Zinsser and Grinnell (18) have shown that the capacity to re- 
act is not transferred passively by means of serum.  After 2 years of 
age the  skin reactions  to protein and autolysate appeared with con- 
siderable frequency.  The mechanism underlying the development of 
this capacity may be contact with organisms, changes that are part of 
physiological growth, or some combination of the two, as in the case 
of the type-specific reactions. 
Immune reactions to type-specific pneumococci occurring in a large 
proportion of individuals might be thought to exert some influence in 
protecting individuals  from  attack,  particularly  since  type-specific 
antibodies are effective prophylactically in animals, and therapeuti- 
cally in man.  But type-specific whole blood bactericidal power has 
been shown to be present in patients early in the course of their dis- 
ease (6, 29-31) and the significance of this type of antibody in protecting 
individuals from lobar pneumonia is  thus questionable.  It may be 
noted, however, that the relative incidence of type-specific bactericidal 
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serum of normal individuals is inversely proportional to the relative 
incidence of lobar pneumonia due to these two types of pneumococci. 
Type III again occupies an anomalous position, with an incidence of 
pneumococcidal power midway between that of Type I  and Type II, 
but with an incidence in pneumonia less than either Type I or Type II. 
Variations  in  the  incidence,  the  clinical  course,  the  pathological 
lesions,  and in the outcome of pneumococcic pneumonia at different 
ages may be stated in general terms.  The morbidity, as influenced by 
age,  is not known, due to lack of direct studies covering all ages in a 
sufficiently  large community; but the curves of deaths from pneumonia 
by ages show a preponderance in infancy and extreme old age that sug- 
gests a higher morbidity as well as an increased case fatality at these 
periods.  At the extremes of life the disease  also  tends to manifest 
fewer of the typical clinical characteristics of lobar pneumonia, as it is 
seen in youth and middle life.  The pathological lesion in pneumonia 
in infancy and old age frequently differs  from that of typical lobar 
pneumonia, being more often lobular in distribution rather than lobar. 
The death rate is high at the two extremes of life, is lowest in youth, 
and gradually increases from youth to old age.  The differences  in the 
incidence of whole blood bactericidal power in infancy and old age, 
the lack of mouse-protective  antibodies in the serum of infants, and the 
lack of capacity of the skin of infants to react to proteins and autoly- 
sates  of  the  pneumococcus may be  related to  these  variations  in 
pneumococcic pneumonia with  age.  Conversely,  the  possession  of 
type-specific antibodies and the capacity of the skin to react to pneu- 
mococcic  proteins and autolysates by a  relatively high proportion of 
adults suggests a relationship between the immune mechanism which 
underlies  these reactions  and  the  occurrence  of  typical  lobar 
pneumonia. 
CONCLUSIONS 
1.  The incidence of pneumococcidal  power of the whole defibrinated 
blood in human beings has been shown to vary with age.  The age 
distribution of other type-specific antibodies varies similarly, insofar 
as they are frequent enough to be compared or technically demon- 
strable. 
2.  The incidence of pneumococcidal  power of the whole defibrinated W. D.  SUTLII~F AIqD MAXWELL  FINLAND  851 
blood for Type I, Type II, and Type III differs.  Type I is the rarest, 
Type II is the most frequent, and Type III is of intermediate frequency. 
The type-specific antibodies responsible for the other tests employed 
show a  similar relative frequency in regard to Types I  and II, but 
some variation in regard to Type III. 
3.  The skin reactions to the acetic acid-predpitable proteins and 
autolysates of the pneumococci are negative or rarely positive in in- 
fants, infrequently positive in childhood, and positive in a  high per- 
centage of adults. 
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